Women’s health

Uterine fibroids
#Gedeon Richter #National Institute for Health and Care Excellence (NICE) #Phase III trial #Uterine fibroids #Women's health

NICE recommends first oral GnRH antagonist for uterine fibroids   

The National Institute for Health and Care Excellence (NICE) has published final guidance recommending Ryeqo (relugolix 40mg, estradiol 1mg, and norethisterone acetate 0.5mg), for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.  The decision makes the relugolix combination therapy… Read More

#News

#New appointment #Recruitment #ValiRx #Women's health

ValiRx appoints interim CSO to drive drug discovery efforts

Life science company ValiRx has appointed Dr Cathy Tralau-Stewart as its interim Chief Scientific Officer (CSO) to help bolster its drug discovery and therapeutic expertise. Dr Tralau-Stewart has over 20 years’ senior academic and industry leadership experience and joins ValiRx from drug discovery company C4X Discovery. At C4X Discovery Dr… Read More

#News